Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)

A. Charehbili; S. van de Ven; V. T. H. B. M. Smit; E. Meershoek-Klein Kranenbarg; N. A. T. Hamdy; H. Putter; J. B. Heijns; L. J. C. van Warmerdam; L. Kessels; M. Dercksen; M. J. Pepels; E. Maartense; H. W. M. van Laarhoven; B. Vriens; M. N. Wasser; A. E. van Leeuwen-Stok; G. J. Liefers; C. J. H. van de Velde; J. W. R. Nortier; J. R. Kroep

doi:10.1093/annonc/mdu102

Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)

A. Charehbili, S. van de Ven, V. T. H. B. M. Smit, E. Meershoek-Klein Kranenbarg, N. A. T. Hamdy, H. Putter, J. B. Heijns, L. J. C. van Warmerdam, L. Kessels, M. Dercksen, M. J. Pepels, E. Maartense, H. W. M. van Laarhoven, B. Vriens, M. N. Wasser, A. E. van Leeuwen-Stok, G. J. Liefers, C. J. H. van de Velde, J. W. R. Nortier, J. R. Kroep^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

27 Citations (Web of Science)

Original language	English
Pages (from-to)	998-1004
Journal	Annals of Oncology
Volume	25
Issue number	5
DOIs	https://doi.org/10.1093/annonc/mdu102
Publication status	Published - May 2014

Keywords

neoadjuvant chemotherapy
zoledronic acid
bisphosphonates
menopausal status

Access to Document

10.1093/annonc/mdu102

Cite this

Charehbili, A., van de Ven, S., Smit, V. T. H. B. M., Meershoek-Klein Kranenbarg, E., Hamdy, N. A. T., Putter, H., Heijns, J. B., van Warmerdam, L. J. C., Kessels, L., Dercksen, M., Pepels, M. J., Maartense, E., van Laarhoven, H. W. M., Vriens, B., Wasser, M. N., van Leeuwen-Stok, A. E., Liefers, G. J., van de Velde, C. J. H., Nortier, J. W. R., & Kroep, J. R. (2014). Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Annals of Oncology, 25(5), 998-1004. https://doi.org/10.1093/annonc/mdu102

Charehbili, A. ; van de Ven, S. ; Smit, V. T. H. B. M. ; Meershoek-Klein Kranenbarg, E. ; Hamdy, N. A. T. ; Putter, H. ; Heijns, J. B. ; van Warmerdam, L. J. C. ; Kessels, L. ; Dercksen, M. ; Pepels, M. J. ; Maartense, E. ; van Laarhoven, H. W. M. ; Vriens, B. ; Wasser, M. N. ; van Leeuwen-Stok, A. E. ; Liefers, G. J. ; van de Velde, C. J. H. ; Nortier, J. W. R. ; Kroep, J. R. / Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). In: Annals of Oncology. 2014 ; Vol. 25, No. 5. pp. 998-1004.

@article{147c043297ee4a588bb712786e604b37,

title = "Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)",

keywords = "neoadjuvant chemotherapy, zoledronic acid, bisphosphonates, menopausal status",

author = "A. Charehbili and {van de Ven}, S. and Smit, {V. T. H. B. M.} and {Meershoek-Klein Kranenbarg}, E. and Hamdy, {N. A. T.} and H. Putter and Heijns, {J. B.} and {van Warmerdam}, {L. J. C.} and L. Kessels and M. Dercksen and Pepels, {M. J.} and E. Maartense and {van Laarhoven}, {H. W. M.} and B. Vriens and Wasser, {M. N.} and {van Leeuwen-Stok}, {A. E.} and Liefers, {G. J.} and {van de Velde}, {C. J. H.} and Nortier, {J. W. R.} and Kroep, {J. R.}",

year = "2014",

month = may,

doi = "10.1093/annonc/mdu102",

language = "English",

volume = "25",

pages = "998--1004",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "5",

}

Charehbili, A, van de Ven, S, Smit, VTHBM, Meershoek-Klein Kranenbarg, E, Hamdy, NAT, Putter, H, Heijns, JB, van Warmerdam, LJC, Kessels, L, Dercksen, M, Pepels, MJ, Maartense, E, van Laarhoven, HWM, Vriens, B, Wasser, MN, van Leeuwen-Stok, AE, Liefers, GJ, van de Velde, CJH, Nortier, JWR & Kroep, JR 2014, 'Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)', Annals of Oncology, vol. 25, no. 5, pp. 998-1004. https://doi.org/10.1093/annonc/mdu102

Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). / Charehbili, A.; van de Ven, S.; Smit, V. T. H. B. M.; Meershoek-Klein Kranenbarg, E.; Hamdy, N. A. T.; Putter, H.; Heijns, J. B.; van Warmerdam, L. J. C.; Kessels, L.; Dercksen, M.; Pepels, M. J.; Maartense, E.; van Laarhoven, H. W. M.; Vriens, B.; Wasser, M. N.; van Leeuwen-Stok, A. E.; Liefers, G. J.; van de Velde, C. J. H.; Nortier, J. W. R.; Kroep, J. R.

In: Annals of Oncology, Vol. 25, No. 5, 05.2014, p. 998-1004.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)

AU - Charehbili, A.

AU - van de Ven, S.

AU - Smit, V. T. H. B. M.

AU - Meershoek-Klein Kranenbarg, E.

AU - Hamdy, N. A. T.

AU - Putter, H.

AU - Heijns, J. B.

AU - van Warmerdam, L. J. C.

AU - Kessels, L.

AU - Dercksen, M.

AU - Pepels, M. J.

AU - Maartense, E.

AU - van Laarhoven, H. W. M.

AU - Vriens, B.

AU - Wasser, M. N.

AU - van Leeuwen-Stok, A. E.

AU - Liefers, G. J.

AU - van de Velde, C. J. H.

AU - Nortier, J. W. R.

AU - Kroep, J. R.

PY - 2014/5

Y1 - 2014/5

KW - neoadjuvant chemotherapy

KW - zoledronic acid

KW - bisphosphonates

KW - menopausal status

U2 - 10.1093/annonc/mdu102

DO - 10.1093/annonc/mdu102

M3 - Article

C2 - 24585721

VL - 25

SP - 998

EP - 1004

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -